Literature DB >> 15588852

Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors.

Giovanna Floridia1, Giulia Grilli, Marco Salvatore, Chiara Pescucci, Patrick S Moore, Aldo Scarpa, Domenica Taruscio.   

Abstract

We have used comparative genomic hybridization to investigate changes in DNA copy number in 20 nonfunctioning endocrine pancreatic tumors. The total number of regional DNA imbalances per tumor showed variation from case to case and high genetic heterogeneity was observed. From 1 to 22 chromosomal anomalies were detected in 13 of the 20 cases evaluated. Overall gains predominated over losses with a ratio of about 3.9:1 (58 gains/15 losses). The mean total number of regions displaying imbalances increased from 1.25 per tumor for benign tumors to 5.25 for malignant tumors, although statistical significance was not reached (P=0.074).

Entities:  

Mesh:

Year:  2005        PMID: 15588852     DOI: 10.1016/j.cancergencyto.2004.04.015

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

Review 1.  Genetics of pancreatic neuroendocrine tumors: implications for the clinic.

Authors:  Antonio Pea; Ralph H Hruban; Laura D Wood
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-28       Impact factor: 3.869

Review 2.  Profiling mTOR pathway in neuroendocrine tumors.

Authors:  S Cingarlini; M Bonomi; V Corbo; A Scarpa; G Tortora
Journal:  Target Oncol       Date:  2012-08-14       Impact factor: 4.493

3.  DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Authors:  Yuchen Jiao; Chanjuan Shi; Barish H Edil; Roeland F de Wilde; David S Klimstra; Anirban Maitra; Richard D Schulick; Laura H Tang; Christopher L Wolfgang; Michael A Choti; Victor E Velculescu; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Nickolas Papadopoulos
Journal:  Science       Date:  2011-01-20       Impact factor: 47.728

Review 4.  The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.

Authors:  Irvin M Modlin; Steven F Moss; Bjorn I Gustafsson; Ben Lawrence; Simon Schimmack; Mark Kidd
Journal:  Langenbecks Arch Surg       Date:  2011-04-27       Impact factor: 3.445

Review 5.  Pathology and molecular genetics of pancreatic neoplasms.

Authors:  Laura D Wood; Ralph H Hruban
Journal:  Cancer J       Date:  2012 Nov-Dec       Impact factor: 3.360

Review 6.  Prognostic factors in gastrointestinal endocrine tumors.

Authors:  Guido Rindi; Tiziana D'Adda; Elisabetta Froio; Giovanni Fellegara; Cesare Bordi
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

7.  Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor.

Authors:  Rene Quevedo; Anna Spreafico; Jeff Bruce; Arnavaz Danesh; Samah El Ghamrasni; Amanda Giesler; Youstina Hanna; Cherry Have; Tiantian Li; S Y Cindy Yang; Tong Zhang; Sylvia L Asa; Benjamin Haibe-Kains; Monika Krzyzanowska; Adam C Smith; Simron Singh; Lillian L Siu; Trevor J Pugh
Journal:  Genome Med       Date:  2020-04-28       Impact factor: 11.117

Review 8.  PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Franziska Briest; Patricia Grabowski
Journal:  Theranostics       Date:  2014-01-29       Impact factor: 11.556

9.  Loss of 11p11 is a frequent and early event in sporadic nonfunctioning pancreatic neuroendocrine neoplasms.

Authors:  Sven-Petter Haugvik; Ludmila Gorunova; Lisbeth Haugom; Anne Mette Eibak; Ivar Prydz Gladhaug; Sverre Heim; Francesca Micci
Journal:  Oncol Rep       Date:  2014-07-11       Impact factor: 3.906

Review 10.  Surgical and molecular pathology of pancreatic neoplasms.

Authors:  Wenzel M Hackeng; Ralph H Hruban; G Johan A Offerhaus; Lodewijk A A Brosens
Journal:  Diagn Pathol       Date:  2016-06-07       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.